


SHA 68

Cat. No.:	HY-108625												
CAS No.:	847553-89-3												
Molecular Formula:	C ₂₆ H ₂₄ FN ₃ O ₃												
Molecular Weight:	445.49												
Target:	Neuropeptide Y Receptor												
Pathway:	GPCR/G Protein; Neuronal Signaling												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>2 years</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 year</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	2 years		-20°C	1 year
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	2 years											
	-20°C	1 year											



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (561.18 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.2447 mL	11.2236 mL	22.4472 mL
		5 mM	0.4489 mL	2.2447 mL	4.4894 mL
10 mM		0.2245 mL	1.1224 mL	2.2447 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	SHA 68 is a potent and selective non-peptide neuropeptide S receptor (NPSR) antagonist with IC ₅₀ s of 22.0 and 23.8 nM for NPSR Asn ¹⁰⁷ and NPSR Ile ¹⁰⁷ , respectively. SHA 68 has limited the blood-brain barrier (BBB) penetration and the activity in neuralgia ^{[1][2]} .
IC₅₀ & Target	IC ₅₀ : 22 nM (Asn ¹⁰⁷) and 23.8 nM (Ile ¹⁰⁷) ^[1]
In Vivo	<p>SHA 68 (i.p.; 5 and 50 mg/kg) reduces NPS-induced horizontal activity and vertical rearing and climbing^[1].</p> <p>SHA 68 (i.v.; 1 mg/kg) has a T_{1/2} of 0.74 hours, a CL of 4.29 mL/min/kg, and a V_{SS} of 2.53 L/kg^[1].</p> <p>SHA 68 (i.p.; 2.5 mg/kg) has a T_{1/2} of 0.43 hours, a CL of 4.56 mL/min/kg^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

Animal Model:	Male C57BL/6 mice age 8-12 weeks ^[1]
Dosage:	5 and 50 mg/kg
Administration:	i.p.
Result:	Reduced NPS-induced horizontal activity and vertical rearing and climbing.
Animal Model:	Male C57BL/6 mice age 8-12 weeks ^[1]
Dosage:	1 mg/kg (Pharmacokinetic Analysis)
Administration:	i.p.
Result:	Had a $T_{1/2}$ of 0.74 hours, a CL of 4.29 mL/min/kg, and a V_{ss} of 2.53 L/kg.

CUSTOMER VALIDATION

- Peptides. 12 August 2022, 170860.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Okamura N, et al. Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor. *J Pharmacol Exp Ther*

[2]. Ensho T, et al. Neuropeptide S increases motor activity and thermogenesis in the rat through sympathetic activation. *Neuropeptides*. 2017 Oct;65:21-27.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA